GZMO Message Board - Msg: 11285471

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (101)	9/17/1999 4:19:00 PM
From: jeffbas	Read Replies (1) of 438

Rick, can you draw any inference that because ATIII is known to be safe for humans that aaATIII will also be safe, and if so will this have positive implications for the length of time needed for the entire discovery to (potential) market timeline? Is it good to have AS/ES ahead in the sense that if something is heard about the progress there, GZMO can take advantage of it, even to the extent of abandoning the project if this class of compounds is ineffective in humans? Is it bad to have AS/ES ahead because if this class of compounds is effective GZMO has to demonstrate that it is an improvement over AS/ES to get FDA approval? I noticed with interest the lower dosage required -- would this be such an "improvement"?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next